Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.24 +0.04 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
3 Stocks You’ll Regret Not Buying Soon: November 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years. 
Via InvestorPlace
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the  
Via Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again. 
Via Benzinga
Topics Artificial Intelligence
1 Gene Therapy Stock to Buy and Hold for the Long Haul
The biotech has what it takes to overcome recent obstacles. 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Why Sarepta Therapeutics Stock Is Crashing Today
There's a plot twist with Sarepta's disappointing clinical results. 
Via The Motley Fool
Is Sarepta Therapeutics Stock a Bad-News Buy?
Analysts still expect some sizable returns from the stock. 
Via The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
Just because a stock is "on sale" doesn't inherently make it worth purchasing. 
Via The Motley Fool
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Sarepta Therapeutics to Present at the UBS Biopharma Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial. 
Via Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to  
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm, P.A.
Via Business Wire
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Why Are Stocks Down Today?
Stocks are down today and investors wondering why have come to the right place as we have an answer to that question! 
Via InvestorPlace
BB Stock Alert: What to Know as BlackBerry Announces CEO Departure
BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week. 
Via InvestorPlace
US Stocks Fall; Pfizer Swings To Q3 Loss
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17.... 
Via Benzinga
Topics Stocks
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial. 
Via InvestorPlace
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.